These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 26922520)

  • 1. Therapeutic equivalence of antipsychotics and antidepressants - A systematic review.
    Cessak G; Rokita K; Dąbrowska M; Sejbuk-Rozbicka K; Zaremba A; Mirowska-Guzel D; Bałkowiec-Iskra E
    Pharmacol Rep; 2016 Apr; 68(2):217-23. PubMed ID: 26922520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching from brand-name to generic psychotropic medications: a literature review.
    Desmarais JE; Beauclair L; Margolese HC
    CNS Neurosci Ther; 2011 Dec; 17(6):750-60. PubMed ID: 21114789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rational use of generic psychotropic drugs.
    Carbon M; Correll CU
    CNS Drugs; 2013 May; 27(5):353-65. PubMed ID: 23620145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs.
    Borgheini G
    Clin Ther; 2003 Jun; 25(6):1578-92. PubMed ID: 12860486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modified Regulatory Pathways to Approve Generic Drugs in the US and a Systematic Review of Their Outcomes.
    Kesselheim AS; Polinski JM; Fulchino LA; Isaman DL; Gagne JJ
    Drugs; 2015 Apr; 75(6):633-50. PubMed ID: 25822610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of generic switching on concerns about medicine and non-persistence among Danish adults in a general practice setting.
    Rathe JØ
    Dan Med J; 2015 Oct; 62(10):B5148. PubMed ID: 26441397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Switch-to-Brand Rates as a Potential Signal for Therapeutic Equivalency of Generic Antidepressants: A Real-World Retrospective Cohort Study.
    Kalaria S; Spence O; Hong K; dosReis S; Gopalakrishnan M
    Clin Pharmacol Ther; 2021 Aug; 110(2):443-451. PubMed ID: 33811324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switch-backs associated with generic drugs approved using product-specific determinations of therapeutic equivalence.
    Gagne JJ; Polinski JM; Jiang W; Dutcher SK; Xie J; Lii J; Fulchino LA; Kesselheim AS
    Pharmacoepidemiol Drug Saf; 2016 Aug; 25(8):944-52. PubMed ID: 27102378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Converting from brand-name to generic clozapine: a review of effectiveness and tolerability data.
    Bobo WV; Stovall JA; Knostman M; Koestner J; Shelton RC
    Am J Health Syst Pharm; 2010 Jan; 67(1):27-37. PubMed ID: 20044366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case reports of the reemergence of psychotic symptoms after conversion from brand-name clozapine to a generic formulation.
    Mofsen R; Balter J
    Clin Ther; 2001 Oct; 23(10):1720-31. PubMed ID: 11726006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of response after switching from brand name to generic formulations: three cases and a discussion of key clinical considerations when switching.
    Margolese HC; Wolf Y; Desmarais JE; Beauclair L
    Int Clin Psychopharmacol; 2010 May; 25(3):180-2. PubMed ID: 20216221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brand-Name Antidepressants Outperform Their Generic Counterparts in Preventing Hospitalization for Depression: The Real-World Evidence from Taiwan.
    Hsu CW; Lee SY; Yang YH; Wang LJ
    Int J Neuropsychopharmacol; 2020 Dec; 23(10):653-661. PubMed ID: 32598470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the effectiveness of brand-name and generic antipsychotic drugs for treating patients with schizophrenia in Taiwan.
    Hsu CW; Lee SY; Wang LJ
    Schizophr Res; 2018 Mar; 193():107-113. PubMed ID: 28629889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Converting patients from brand-name clozapine to generic clozapine.
    Sajbel TA; Carter GW; Wiley RB
    Ann Pharmacother; 2001 Mar; 35(3):281-4. PubMed ID: 11261523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generic antiepileptic drugs-Safe or harmful in patients with epilepsy?
    Holtkamp M; Theodore WH
    Epilepsia; 2018 Jul; 59(7):1273-1281. PubMed ID: 29894004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brand name versus generic warfarin: a systematic review of the literature.
    Dentali F; Donadini MP; Clark N; Crowther MA; Garcia D; Hylek E; Witt DM; Ageno W;
    Pharmacotherapy; 2011 Apr; 31(4):386-93. PubMed ID: 21449627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: A field test of the FDA bioequivalence standard.
    Ting TY; Jiang W; Lionberger R; Wong J; Jones JW; Kane MA; Krumholz A; Temple R; Polli JE
    Epilepsia; 2015 Sep; 56(9):1415-24. PubMed ID: 26201987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacotherapy considerations in patients with HIV and psychiatric disorders: focus on antidepressants and antipsychotics.
    Hill L; Lee KC
    Ann Pharmacother; 2013 Jan; 47(1):75-89. PubMed ID: 23341158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychiatrists' decision making between branded and generic drugs.
    Hamann J; Mendel R; Kissling W; Leucht S
    Eur Neuropsychopharmacol; 2013 Jul; 23(7):686-90. PubMed ID: 23021566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.